Combination Trial of BMS-690514 in Combination With FOLFIRI and FOLFOX

Inclusion Criteria: * Patients eligible for FOLFIRI or FOLFOX therapy * ECOG performance status score 0-1 * At least 4 weeks since the last chemotherapy, immunotherapy or radiotherapy with: * At least 4 weeks since anti-cancer hormonal therapy OR targeted therapy (for instance tamoxifen or Tarceva) * No maximum age for Study Arm A (FOLFOX) * 18-65 years of age for Study Arm B (FOLFIRI) Exclusion Criteria: * Treatment with other TKIs within the past 4 weeks * Active inflammatory bowel disease * Major gastrointestinal surgery which may affect absorption of the drug, any surgery within the last 4 weeks * History of thromboembolism * Severe unmanageable diarrhea * Uncontrolled or significant cardiovascular disease